Why the study?
Few treatments exist for fatty liver disease beyond lifestyle modification, which is difficult for most patients to achieve, though new therapies like resmetirom and ongoing phase 3 trials are emerging.
The recent FDA approval of resmetirom marks a new era of pharmacological treatments for MAFLD and MASH beyond lifestyle modifications.
May support resmetirom use in MASH; leaves open integration with cirrhosis and portal hypertension management.
Fatty liver disease is a commonly occurring disease resulting in hepatic and extrahepatic complications. To date, there have been few available treatments beyond conventional lifestyle modification. While lifestyle modifications resulting in weight loss >10% have shown to be beneficial for metabolic dysfunction‐associated steatohepatitis (MASH), for the majority of patients, this is difficult to achieve. The recent approval of resmetirom (a thyroid hormone receptor beta agonist) by the Food and Drug Administration following positive results for histological outcomes in a phase 3 trial has opened the door for new treatments for metabolic (dysfunction)‐associated fatty liver disease (MAFLD) and MASH. There are currently a number of phase 3 trials targeting a variety of signaling pathways involved in the pathogenesis of metabolic steatohepatitis that are also promising. This review focuses on the currently available treatments for MAFLD and MASH, ongoing phase 3 clinical trials, and unresolved controversies in clinical trials in this area.
No takes yet. Share an insight, caveat, or question.
Cameron Gofton (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: